Premium
Superselective high‐dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses
Author(s) -
Homma Akihiro,
Oridate Nobuhiko,
Suzuki Fumiyuki,
Taki Shigenari,
Asano Takeshi,
Yoshida Daisuke,
Onimaru Rikiya,
Nishioka Takeshi,
Shirato Hiroki,
Fukuda Satoshi
Publication year - 2009
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.24515
Subject(s) - medicine , concomitant , paranasal sinuses , nasal cavity , radiation therapy , adverse effect , surgery , cancer , nose , cisplatin , chemotherapy
BACKGROUND: The current study aimed to evaluate the efficacy of superselective high‐dose cisplatin infusion with concomitant radiotherapy (RADPLAT) for previously untreated patients with advanced cancer of the nasal cavity and paranasal sinuses. METHODS: Between October 1999 and December 2006, 47 patients were given superselective intra‐arterial infusions of cisplatin (100‐120 mg/m 2 per week) with simultaneous intravenous infusions of thiosulfate to neutralize cisplatin toxicity and conventional external‐beam radiotherapy (65‐70 grays). RESULTS: There were 7 patients (14.9%) diagnosed with T3, 22 (46.8%) with T4a, and 18 (38.3%) with T4b disease. During the median follow‐up period of 4.6 years, the 5‐year local progression‐free survival rate was 78.4% for all patients (n = 47), 69.0% for patients with T4b disease (n = 18), and 83.2% for patients with